Ftse Mib
35.355,87
0,58%
DAX
18.869,36
0,78%
S&P 500
5.308,15
1,17%
NASDAQ
16.740,92
1,39%
Bitcoin
65.837,17
6,97%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Purple Biotech Ltd (PPBT) Purple Biotech Ltd (PPBT) Notizie

Purple Biotech Ltd

PPBT
0,508
-0,002 (-0,39%)
Ultimo aggiornamento: 21:49:18
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Ricevuta di Deposito
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
25/4/202413:00GLOBEPurple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer..
28/3/202412:00GLOBEPurple Biotech to Present New Data On its Oncology Drug..
14/3/202412:30GLOBEPurple Biotech Reports Preclinical Proof of Concept for its..
06/3/202422:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/3/202422:00EDGAR2Form 20-F - Annual and transition report of foreign private..
05/3/202413:58EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/3/202413:55GLOBEPurple Biotech Reports Fourth Quarter and Full-Year 2023..
27/2/202413:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
27/2/202413:00GLOBEPurple Biotech Presents Data of its Phase 1 Head & Neck..
13/2/202413:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/2/202413:00GLOBEPurple Biotech Convenes a Head & Neck Cancer Scientific..
01/2/202413:40EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/2/202413:30GLOBEPurple Biotech Reaches Recommended Phase 2 Dose for NT219
26/1/202422:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/12/202314:06EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/12/202314:05GLOBEPurple Biotech Appoints Dr. Yael Margolin to its Board of..
14/12/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/12/202312:50GLOBEPurple Biotech Completes Patient Enrollment in Phase 2..
21/11/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/11/202312:50GLOBEPurple Biotech Reports Third Quarter 2023 Financial Results
15/11/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
14/11/202322:13EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
13/11/202322:11EDGAR2Form F-1/A - Registration statement for certain foreign..
02/11/202312:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/11/202312:00GLOBEPurple Biotech Fortifies NT219 Patent Protection
30/10/202321:30EDGAR2Form F-1 - Registration statement for certain foreign..
19/10/202322:40EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
19/10/202322:17EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19/10/202321:55GLOBEPurple Biotech Announces Closing of $5 Million Registered..
19/10/202316:36EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19/10/202316:27EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
17/10/202314:02EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/10/202314:00GLOBEPurple Biotech Announces $5 Million Registered Direct..
17/10/202313:03EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
13/10/202313:09EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/10/202314:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/10/202313:50GLOBEPurple Biotech Reports Potential Biomarker Data Support..
03/10/202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/10/202313:50GLOBEPurple Biotech Reports Positive Interim and Preliminary..
21/9/202314:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/9/202314:00GLOBEPurple Biotech to Present New CM24 Pancreatic Cancer..
13/9/202314:39EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/8/202315:29GLOBEPurple Biotech Reports Second Quarter 2023 Financial Results
22/8/202314:22EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/7/202314:20EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/7/202314:15GLOBEPurple Biotech Reports Positive Results of CM24 Dose..
Apertura: 0,54 Min: 0,50 Max: 0,54
Chiusura: 0,51

La tua Cronologia

NASDAQ
PPBT
Purple Biotech
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network